Evofem Biosciences sells $260k Series F-1 Preferred Stock to Aditxt in private placement

Evofem Biosciences, Inc.

Sold 260 shares of Series F-1 Preferred Stock to Aditxt for $260,000 on September 20, 2024.
Preferred shares are convertible into common stock; registration rights agreement requires filing within 300 days.
Private placement is part of consideration under the Amended Merger Agreement with Aditxt (previously disclosed).
Securities issued in reliance on Section 4(a)(2) exemption from registration under the Securities Act.
Company must use best efforts to have registration statement declared effective within 90 days of filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.